Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

A new study from the University of Oxford has revealed a surprising benefit of the respiratory syncytial virus (RSV) vaccine: ...

The new RSV recommendation calls for a single dose of vaccine for adults age 50 to 59 years who are at increased risk of ...

The expanded recommendation is good news for Moderna, Pfizer, and GSK, which all sell RSV vaccines for older adults. Moderna ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50 instead of 60 ...

June 17, 2025 – The FDA has expanded the use of Moderna's respiratory syncytial virus (RSV) shot to all adults, with some limits on who can get it. First approved in 2024 for people 60 or older ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants.

Infant RSV hospitalisations fell 69 per cent in Spain during the 2024 to 2025 season compared with the 2022 to 2023 season, when immunisation therapies were unavailable.

The monoclonal antibody shot, which was approved by Health Canada in 2023 and is given in a single dose, contains lab-made proteins that act like those created by the body's own immune system.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease by 63% over three ...

New RSV shot not available to Alberta newborns as virus season ramps up So far this respiratory virus season, 67 Albertans have died due to RSV, including 57 over the age of 60.

For example, over the 2024 RSV season in Argentina, it was found to prevent 72.7% of lower respiratory tract infections caused by RSV and requiring hospitalisation in infants aged 0–3 months ...